title: Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation.
abstract: BACKGROUND
  The alleged efficacy of pharmaceutical industry self-regulation has been used to repudiate increased government oversight over promotional activity. European politicians and industry have cited Sweden as an excellent example of self-regulation based on an ethical code. This paper considers antidepressant advertising in Sweden to uncover the strengths and weaknesses of self-regulation.
  
  
  METHODS
  We analyzed all antidepressant advertisements in the Swedish Medical Journal, 1994-2003. The regulation of these advertisements was analyzed using case reports from self-regulatory bodies. The authors independently reviewed this material to investigate: (1) extent of violative advertising; (2) pattern of code breaches; (3) rate at which the system reacted to violative advertising; (4) prevalence of and oversight over claims regarding antidepressant efficacy and disease causality, and (5) costs for manufactures associated with violative advertising.
  
  
  RESULTS
  Self-regulatory bodies identified numerous code breaches. Nonetheless, they failed to protect doctors from unreliable information on antidepressants, since as many as 247 of 722 (34%) advertisements breached the industry code. Self-regulatory bodies repeatedly failed to challenge inflated claims of antidepressant efficacy, lending evidence of lax oversight. On average, 15 weeks elapsed between printing and censure of a wrongful claim, and in 25% of cases 47 weeks or more elapsed. Industry paid roughly €108000 in fines for violative advertising, adding an estimated additional average cost of 11% to each purchased violative advertisement, or amounting to as little as 0.009% of total antidepressant sales of around €1.2 billion.
  
  
  CONCLUSIONS
  Lax oversight, combined with lags in the system and low fines for violations, may explain the Swedish system's failure to pressure companies into providing reliable antidepressants information. If these shortcomings prove to be consistent across self-regulatory settings, and if appropriate measures are not taken to amend shortcomings, many countries may want to reconsider the current balance between self-regulation, and legislative control with government oversight.
authors: Department of Clinical Sciences, Lund University, Malmö, Sweden.
authors: Anna V
authors: AV
authors: Zetterqvist
authors: Shai
authors: S
authors: Mulinari
mesh_terms: D000329:Advertising / Q000191:economics*; D000928:Antidepressive Agents; D004345:Drug Industry / Q000191:economics / Q000941:ethics / Q000331:legislation & jurisprudence; D005607:Fraud; D006801:Humans; D007880:Legislation, Drug; D010506:Periodicals as Topic; D012927:Social Control, Informal; D013548:Sweden
chemical_list: D000928:Antidepressive Agents
references: N Engl J Med. 2008 Jan 17;358(3):252-60
references: 18199864
references: Pharmacoeconomics. 2008;26(7):603-16
references: 18563951
references: Neth J Med. 2010 Jan;68(1):46-9
references: 20103825
references: Sociol Health Illn. 2013 Jun;35(5):761-77
references: 23094890
references: Arch Gen Psychiatry. 2009 Aug;66(8):848-56
references: 19652124
references: Global Health. 2012 Jul 11;8:24
references: 22784944
references: J Pharm Bioallied Sci. 2011 Jul;3(3):403-6
references: 21966161
references: J Indian Med Assoc. 1997 Jan;95(1):19-20
references: 9212565
references: J Hist Neurosci. 2012;21(4):366-92
references: 22947380
references: PLoS Med. 2005 Dec;2(12):e392
references: 16268734
references: Med J Aust. 2005 Jul 18;183(2):73-4
references: 16022611
references: PLoS One. 2009 Jul 22;4(7):e6350
references: 19623259
references: PLoS Med. 2008 Feb;5(2):e45
references: 18303940
references: Eur Neuropsychopharmacol. 2008 Sep;18(9):623-7
references: 18621509
references: BMC Public Health. 2010 May 29;10:294
references: 20509953
references: Lancet. 2003 Mar 8;361(9360):878-9
references: 12642074
references: Pharmacoepidemiol Drug Saf. 2004 Nov;13(11):789-95
references: 15486957
references: Lakartidningen. 2011 Sep 21-27;108(38):1839-40
references: 22111217
references: Am J Bioeth. 2003 Summer;3(3):49-50
references: 14594491
references: Arch Gen Psychiatry. 1974 Apr;30(4):447-51
references: 4273761
references: BMJ. 2003 May 31;326(7400):1171-3
references: 12775615
references: Lancet. 2003 Jan 4;361(9351):27-32
references: 12517463
references: Br J Psychiatry. 2012 May;200(5):393-8
references: 22442100
references: N Engl J Med. 1990 Aug 30;323(9):616-7
references: 2381456
references: PLoS Med. 2006 May;3(6):e130
references: 16637744
references: BMJ. 2005 Nov 26;331(7527):1225
references: 16308367
references: PLoS One. 2011;6(8):e23336
references: 21858076
references: CMAJ. 1997 Feb 1;156(3):351-6
references: 9033415
references: Int J Clin Pract. 2010 Jul;64(8):1015-8
references: 20642702
references: Lakartidningen. 2012 Nov 14-20;109(46):2106-7
references: 23259219
references: PLoS Med. 2010 Oct 19;7(10):e1000352
references: 20976098
references: BMJ. 1990 Feb 3;300(6720):307-11
references: 2106963
references: J Nerv Ment Dis. 2008 Apr;196(4):267-73
references: 18414120
references: Rheumatology (Oxford). 2006 Sep;45(9):1154-7
references: 16531437
references: Arch Gen Psychiatry. 1997 Jul;54(7):597-606
references: 9236543